The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group.
about
Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney diseaseStandards of medical care in diabetes--2012Transcriptomics: A Step behind the Comprehension of the Polygenic Influence on Oxidative Stress, Immune Deregulation, and Mitochondrial Dysfunction in Chronic Kidney DiseaseEffect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analysesPresent and future in the treatment of diabetic kidney diseaseRenin-Angiotensin-aldosterone system in diabetes and hypertensionStandards of medical care in diabetes--2013Clinical problem solving based on the 1999 Canadian recommendations for the management of hypertension.1999 Canadian recommendations for the management of hypertension. Task Force for the Development of the 1999 Canadian Recommendations for the Management of HypertensionStandards of medical care in diabetes--2010.Diabetic Kidney Disease: A Syndrome Rather Than a Single Disease.Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials.Microalbuminuria in diabetes mellitus.To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy.Blood pressure in diabetic nephropathy--current controversies.Standards of medical care in diabetes--2011.What should the role of ACE inhibitors be in the treatment of diabetes? Lessons from HOPE and MICRO-HOPE.Risk for ESRD in type 1 diabetes remains high despite renoprotection.Calcium channel blockade in combination with angiotensin-converting enzyme inhibition or angiotensin II (AT(1)-receptor) antagonism in hypertensive diabetics and patients with renal disease and hypertension.Prevention of chronic kidney disease and subsequent effect on mortality: a systematic review and meta-analysis.The renin-angiotensin system and the long-term complications of diabetes: pathophysiological and therapeutic considerations.Safety and tolerability of fixed antihypertensive combinations in blood pressure control: focus on olmesartan medoxomil and amlodipine combinationMicroalbuminuria as a marker of cardiovascular and renal risk in type 2 diabetes mellitus: a temporal perspective.High risk of ESRD in type 1 diabetes: new strategies are needed to retard progressive renal function declinePrescription Pattern of Antihypertensive Agents in T2DM Patients Visiting Tertiary Care Centre in North India.Improving outcomes in diabetes and chronic kidney disease: the basis for Canadian guidelinesThe role of angiotensin II type 1 receptor blockers in the prevention and management of diabetes mellitus.Urinary total protein as the predictor of albuminuria in diabetic patientsStandards of medical care in diabetes--2009.Magnitude of underascertainment of impaired kidney function in older adults with normal serum creatinineFactors associated with microalbuminuria in 7,549 children and adolescents with type 1 diabetes in the T1D Exchange clinic registry.Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus.Urinary biomarkers for the early diagnosis of retinopathy and nephropathy in type 1 diabetes mellitus: a "steady stream" of information using proteomics.Progressive renal decline as the major feature of diabetic nephropathy in type 1 diabetes.Predictors of HIV-associated nephropathy.Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria.Microalbuminuria: a marker to increased renal and cardiovascular risk in diabetes mellitus.Prevention of diabetic nephropathy.Effect of a pharmacist-managed diabetes care program in a free medical clinic.Comparative pharmacokinetics and pharmacodynamics of amlodipine in hypertensive patients with and without type II diabetes mellitus.
P2860
Q24244197-8B40B00A-E56D-4329-8D89-785DD0D7CBAFQ24632533-5C720F4E-72DB-4BC4-BD2C-52F4209C6DD4Q26740125-CF6637A4-61E4-4618-A21E-8E0EA0B22ED9Q26766025-1C7C4D0F-2008-44AB-84D1-CC3C26164116Q26864133-4B118C95-C7F7-4818-B0C0-AD18CC468CE4Q28308222-EED226A6-146F-403B-A808-9C48ACF316D9Q29620309-4F5158A6-5D14-4299-A251-1C9A7F9C506CQ30499043-99AE67CC-2E05-4AB7-BBB3-7614BD743199Q30499045-92930E07-E987-40D8-8138-D72F7473A3CEQ33554238-16EE124C-22ED-4948-8BCE-208B3F1408F3Q33583012-CFEFBDA8-942E-4D52-B52E-6E1E04730C73Q33836604-BA41ECDE-0D28-445E-9F49-30D3E48E01B0Q34004759-C932EA5F-A5D5-4CC4-AD2F-532068CE55F0Q34037255-7CEA503D-96E6-4A51-8E9E-51EC59F0804EQ34212822-FB705D7B-86A9-4E43-B73E-A0B7FF0BBA43Q34425055-93711149-8546-4A89-AB42-68E909EBB03AQ34530229-4FAA3771-38CA-44DD-A09F-6B4E3E68F0E1Q34695426-516C4D92-D5D2-4010-94EE-04CAC6594C63Q34849534-62F2E260-6C7A-4E21-93F9-F9A0830A6D08Q34979484-C0CDC6D3-5C50-41C6-A0BB-31D81D2F7119Q35182095-A6599C6D-F3C6-4A0D-97A8-10EB7D94483BQ35210547-51B8FD1F-0632-43D2-8B48-BE1BA03C5DCCQ35648485-2656D68D-F921-4248-86E2-7F06110081E0Q36328889-6FA38DD0-6ED8-47AD-BBD6-B1A5DD9EC369Q36506965-78192B1C-78C0-46C5-8298-E53E3F769A05Q36834059-03056BA6-FBAF-4564-9A9B-2C2386A66A93Q36909521-59275EF6-1E06-4ACE-882B-324062F468DFQ36957392-7C03C80E-0F43-408E-A9BC-4D82420934A6Q37036416-A113C53B-303B-42F7-9D3B-F4ECD459508FQ37104269-0BAEFFF4-AFC4-4273-B6CA-6E3024073688Q37106486-2B4CA0E6-A03A-4E79-8191-F5467A18FCE8Q37370706-065887E6-4E37-4F84-B016-D2BEC04F4A98Q37634057-A9D4D5DD-FF1F-4C4C-ABBA-ACDB0F1E0E54Q38161868-FD18E65F-9459-4B34-B545-F523BF65BB80Q38198151-E4E0DA35-A203-4E47-BBBF-B96C919A96A0Q38638695-E97D3450-A9B2-4DE0-9E68-B569817D1D8DQ40884232-A175DB7B-A040-499B-A4C4-E39C00EF0BC0Q41353971-2F503696-7DAF-4BC2-9AFD-325CDB02361CQ41756482-3E2753D3-418A-4D56-939C-962FE8FB1E4DQ43791588-BB46F0D7-BAB9-48EA-AD0D-5E2F2A228BB9
P2860
The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
The beneficial effect of angio ...... Microalbuminuria Study Group.
@en
The beneficial effect of angio ...... Microalbuminuria Study Group.
@nl
type
label
The beneficial effect of angio ...... Microalbuminuria Study Group.
@en
The beneficial effect of angio ...... Microalbuminuria Study Group.
@nl
prefLabel
The beneficial effect of angio ...... Microalbuminuria Study Group.
@en
The beneficial effect of angio ...... Microalbuminuria Study Group.
@nl
P2093
P1476
The beneficial effect of angio ...... Microalbuminuria Study Group.
@en
P2093
P304
P356
10.1016/S0002-9343(99)80226-5
P407
P577
1995-11-01T00:00:00Z